- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT04816630
Feasibility Study of Hematology Parameters in COVID-19 Disease
Feasibility Study to Evaluate Performance of MDW and Other Hematology Parameters for Identification of COVID-19 Disease and Clinical Progression in Adult Hospitalized Patients - Washington University
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The objective of this study is to evaluate MDW and/or combination(s) of hematology parameters that best identify patients with COVID-19 disease who tested SAR-CoV-2 positive by standard of care (SOC) COVID-19 testing.
A feasibility study of consecutive adult patients who presented to the hospital with symptoms suggestive of COVID-19 or respiratory infection and whose standard of care testing involves a CBC-DIFF and microbial testing including RT-PCR testing for SARS-CoV-2 will be enrolled. This study will evaluate MDW and other CPD parameters performance in COVID-19 patients and the ability of MDW to identify RT-PCR positive COVID-19 patients as well as potential added value to RT-PCR tests of MDW. A minimum of 50 COVID-19 positive and 150 COVID-19 negative patients meeting inclusion criteria will be evaluated. Patients with symptoms suggestive of COVID-19 and who have RT-PCR test samples drawn will be retested on the DxH900 hematology analyzer to capture baseline MDW results. In addition, a retrospective data extraction will be performed for those patient samples tested during the Post Market study during the COVID-19 pandemic that meet the revised study population.
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
Missouri
-
Saint Louis, Missouri, Förenta staterna, 63110
- Washington University
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Adult patients [18-89 years of age]
- Present to the Emergency Department
- With symptoms suggestive of COVID-19 or respiratory infection
- Whose assessment includes CBC-Diff and RT-PCR testing
Exclusion Criteria:
- Pregnancy
- Prisoners
- <18 years of age
- >89 years of age
- Previously evaluated in this study
- No RT-PCR testing
- Sample age >2 hours from time of draw
- Instrument flags, including vote outs and review flags for the MDW parameter
- Samples stored in refrigerated temperatures
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
Intervention / Behandling |
|---|---|
|
CBC-Diff Monocyte Volume Width Distribution
Monocyte Distribution Width [MDW] is part of the CBC with Differential.
No intervention
|
MDW is part of the CBC-Diff and will be collected but not reported to the physician.
MDW will not impact standard of care.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
COVID-19 diseased patients
Tidsram: Within 12 hours from presentation to the emergency department
|
MDW's ability to identify COVID-19 negative versus COVID-19 positive patients using RT-PCR
|
Within 12 hours from presentation to the emergency department
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
COVID-19 diseased patients diagnosed clinically
Tidsram: Within 12 hours from presentation to the emergency department
|
MDW's ability to identify COVID-19 diseased patients versus site's COVID-19 diagnosis, including those that were RT-PCR negative
|
Within 12 hours from presentation to the emergency department
|
Andra resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Initial Disposition: Hospitalization
Tidsram: Within 12 hours from presentation to the emergency department
|
MDW's ability to identify COVID-19 patients who require hospitalization
|
Within 12 hours from presentation to the emergency department
|
|
Initial Disposition: ICU Admission
Tidsram: Within 12 hours from presentation to the emergency department
|
MDW's ability to identify COVID-19 patients who require treatment in the intensive care unit
|
Within 12 hours from presentation to the emergency department
|
|
Increased Respiratory Requirements such as Non-invasive and Invasive Mechanical Interventions
Tidsram: Within 72 hours from presentation to the emergency department
|
MDW's ability to identify COVID-19 patients upon emergency department that may require increased respiratory requirements in 72 hours from presentation
|
Within 72 hours from presentation to the emergency department
|
|
COVID-19 Severity
Tidsram: Within 12 hours from presentation to the emergency department
|
MDW's ability to identify COVID-19 patient severity [mild, moderate, severe and critical]
|
Within 12 hours from presentation to the emergency department
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- C71934
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
produkt tillverkad i och exporterad från U.S.A.
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .